NewsBenzingaRevolution Medicines Presents Exploratory Subgroup Analyses From Phase 3 RASolute 302 Trial, As Late-Breaking Abstract At ESMO Congress 2026 Revolution Medicines Presents Exploratory Subgroup Analyses From Phase 3 RASolute 302 Trial, As Late-Breaking Abstract At ESMO Congress 2026 Benzinga 2026.10.23 11:31 (GMT+0) Open on Benzinga Other news IBM Stock Moves Lower: What's Going On? JP Morgan Maintains Overweight on Itau Unibanco Holding, Lowers Price Target to $9 Amazon’s Big Week: First a New James Bond, Then Anthropic’s IPO JP Morgan Maintains Overweight on Allstate, Lowers Price Target to $291 TELUS Shares Rise After Québecor Submits Unsolicited Acquisition Proposal NVIDIA's Leadership Vacuum Hands AMD Its Biggest Opportunity in Years: Analysts